Oral Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer
Condition:   HER2-positive Breast Cancer Intervention:   Drug: Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab) Sponsors:   Institut Curie;   Seagen Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 21, 2023 Category: Research Source Type: clinical trials